ViewRay® to Participate in the B. Riley Securities Oncology Conference

Rhea-AI Summary

ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Securities Oncology Conference on January 28, 2022, at 1:00 p.m. ET. CEO Scott Drake and CFO Zach Stassen will engage in a fireside chat during the event. Investors can access an audio webcast of the presentation on the investor relations section of the company's website, with a replay available for seven days post-event. ViewRay specializes in MR-guided radiation therapy with its MRIdian system, designed to enhance radiation oncology workflows.

News Market Reaction – VRAY

-1.12%

-1.12% Session move

In the trading session that priced this news, VRAY declined 1.12%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, Jan. 25, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 1:00 p.m. Eastern Time on Friday, January 28, 2022.

An audio webcast of the Company's presentation will be available on the investor relations section of ViewRay's website at http://investors.viewray.com/events-and-presentations/upcoming-events. A replay of the webcast will be available for 7 days after the date of the presentation.

About ViewRay^®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian^® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

View original content:https://www.prnewswire.com/news-releases/viewray-to-participate-in-the-b-riley-securities-oncology-conference-301467337.html

SOURCE ViewRay, Inc.

FAQ

What is the date and time of ViewRay's participation in the B. Riley Securities Oncology Conference?

ViewRay will participate on January 28, 2022, at 1:00 p.m. Eastern Time.

Who will represent ViewRay at the B. Riley Securities Oncology Conference?

Scott Drake, CEO, and Zach Stassen, CFO, will represent ViewRay.

Where can I find the audio webcast of ViewRay's presentation?

The audio webcast will be available on ViewRay's investor relations website.

How long will the replay of ViewRay's presentation be available?

The replay of the webcast will be available for seven days after the presentation.

What product does ViewRay specialize in?

ViewRay specializes in the MRIdian MR-guided radiation therapy system.